Skip to content

Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial

Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07659730
Acronym
OPIOID CITY FR
Enrollment
772
Registered
2026-06-22
Start date
2026-07-02
Completion date
2029-12-01
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperatoire Medicine, Surgery

Keywords

Perioperative, Surgery, Patient Reported Outcomes Mesuares (PROMs), persistent opioid use

Brief summary

The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Follow-up is delivered by specifically trained nurses and embedded in a decompartmentalized care model combining in-person and remote interactions, integrating hospital teams and primary care professionals within a coordinated pathway. OPTIMISTE was recently evaluated in a multicenter randomized controlled trial, the SUPPORT study (NCT06182254), which included 280 patients. The study demonstrated a significant impact of PROM-based follow-up on perceived recovery at postoperative day 35, and more importantly, an approximately 50% reduction in the proportion of patients with persistent opioid use at that time point. Although this was a secondary endpoint, the findings suggest that active postoperative monitoring centered on patient-reported outcomes and rapidly relayed to community care providers represents a major lever for preventing opioid misuse after surgery. However, these results require further confirmation and refinement. First, the effect on persistent opioid consumption needs to be validated as a primary endpoint. Second, despite the benefit observed, more than 12% of patients in the intervention group still exhibited persistent opioid use five weeks after surgery, compared with 21% in the control group. This residual persistence, although reduced, remains clinically concerning and indicates that the current OPTIMISTE model does not yet fully prevent unanticipated prolonged opioid exposure. The hypothesis of the present protocol is that the effectiveness of OPTIMISTE in reducing postoperative persistent opioid use can be strengthened through earlier, more individualized and primary-care-driven management. This enhancement relies on better mobilization of community healthcare professionals - general practitioners, community nurses and pharmacists - supported by digital health tools and reinforced coordination channels such as secure platforms, teleconsultations and structured transmission of PROM scores. By systematically integrating primary care providers into longitudinal postoperative follow-up guided by PROMs, the protocol aims to improve therapeutic responsiveness, reduce unjustified prolonged prescriptions and promote early tapering when clinically appropriate. The objective is to optimize hospital-community coordination in order to amplify the impact of the OPTIMISTE pathway on patient-perceived recovery and opioid stewardship. Ultimately, this research seeks to demonstrate that strengthening the role of primary care, combined with fine-grained assessment of patient-reported recovery, represents an effective, ethical and scalable strategy to improve the quality, safety and efficiency of postoperative care pathways while sustainably reducing persistent opioid use at both individual and population levels.

Detailed description

The study is an open-label, multicenter, randomized controlled trial comparing two groups: 1. Control group Participants in the control group receive the usual conventional postoperative follow-up, notably by the surgeon and the attending physician. 2. Experimental group In addition to the usual conventional follow-up, participants in the experimental group benefit from a comprehensive, closely coordinated care pathway between hospital and primary care, based on active collaboration with community healthcare professionals. This enhanced follow-up includes: * Establishment of a personalized recovery trajectory, * Early identification of any delay or difficulty in the recovery process, * Adaptation of follow-up and adjustment of the care pathway in response to potential complications, * Generation of a personalized report transmitted to the general practitioner to facilitate ongoing care, * Simplified access to specialist consultations if clinically required, and * a pharmaceutical consultation with the community pharmacist to optimize and secure medication use. The program also integrates specially trained nurses who assess patients' health status according to their own perception (OPTIMISTE follow-up). From postoperative day 14 onward, if a risk of persistent opioid use is identified, a coordinated intervention between hospital and community care is initiated to ensure timely therapeutic adjustments, promote appropriate tapering, and prevent unjustified prolonged opioid exposure.

Interventions

Tip: Ensure that this name matches the name used in the associated Arm Description. Patient Reported Outcomes based perioperative follow-up. Description - Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) The Patient-Reported Outcomes-based perioperative follow-up is a patient-centered approach that evaluates postoperative recovery using standardized questionnaires completed directly by the patient. This method highlights the patient's own perception of recovery-covering physical comfort, emotional state, independence, and pain control-rather than relying solely on clinical or physiological parameters. The Quality of Recovery-15 (QoR-15) score is a validated, short-form tool designed to measure the quality of postoperative recovery from the patient's perspective. It consists of 15 items covering five key dimensions: 1. Physical comfort (pain, nausea, general well-being) 2. Emotional state (anxiety, depression, feeling of support) 3. Psychological support

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The study is an open-label, multicenter, randomized controlled trial comparing two groups

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female * Adult patient, with no upper age limit * Undergoing scheduled or unscheduled surgery in a center participating in the research * Subject affiliated to a social health insurance scheme * Subject able to understand the objectives and risks related to the research and to give informed consent, dated and signed

Exclusion criteria

* Inability to administer the mQoR-15f questionnaire (cognitive disorders, language barrier) * Patient who has already received previous follow-up by the OPTIMISTE team * Patient enrolled in a therapeutic trial that may affect post-operative recovery quality. * Pregnant or breastfeeding woman * Inability to provide the subject with informed information (subject in an emergency situation, difficulties in understanding, etc.) * Subject under legal protection, guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
The main objective is to Evaluate the impact of a structured hospital-community follow-up on persistent opioid use in primary care 90 days after a surgical procedure.between baseline consultation and "day 90"Persistent opioid use at postoperative day 90 is defined as the use of a weak or strong opioid at least once per week. This definition includes all weak opioids (WHO class 2) and strong opioids (WHO class 3), regardless of dosage form (e.g., immediate-release or extended-release) or route of administration (e.g., oral or transdermal).

Contacts

CONTACTMonia BEN HADJ HAMED
monia.ben-hadj-hamed@chru-strasbourg.fr+33388616711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026